mRNA Vaccines and Therapeutics Combine Power and Finesse

Q4 Biochemistry, Genetics and Molecular Biology

Genetic Engineering & Biotechnology News Pub Date : 2023-11-01 DOI:10.1089/gen.43.11.07

Kathy Liszewski

引用次数: 0

Abstract

Genetic Engineering & Biotechnology NewsVol. 43, No. 11 Infectious DiseasemRNA Vaccines and Therapeutics Combine Power and FinessePlatforms for developing mRNA vaccines and therapeutics offer potent payloads, targeted delivery, and durable expression, as well as smooth paths to manufacturingKathy LiszewskiKathy LiszewskiSearch for more papers by this authorPublished Online:9 Nov 2023https://doi.org/10.1089/gen.43.11.07AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 43Issue 11Nov 2023 Information© 2023 by GEN PublishingTo cite this article:Kathy Liszewski.mRNA Vaccines and Therapeutics Combine Power and Finesse.Genetic Engineering & Biotechnology News.Nov 2023.18-20, 22.http://doi.org/10.1089/gen.43.11.07Published in Volume: 43 Issue 11: November 9, 2023PDF download

查看原文本刊更多论文

mRNA疫苗和疗法结合了力量和技巧

基因工程与生物技术新闻卷。43, No. 11传染病rna疫苗和治疗方法结合力量和精细开发mRNA疫苗和治疗方法的平台提供有效载荷，靶向递送和持久表达。以及顺利的制造路径kathy LiszewskiKathy liszewski搜索本文作者的更多论文出版在线:2023年11月9日https://doi.org/10.1089/gen.43.11.07AboutSectionsView文章查看全文pdf /EPUB权限& CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites返回出版物ShareShare onFacebookTwitterLinked InRedditEmail查看文章figuresreferencesrelateddetails Volume 43Issue 11Nov 2023信息©2023 by GEN publishing引用此文章:凯西Liszewski。mRNA疫苗和疗法结合了力量和技巧。基因工程与生物技术新闻。2023.11月18- 20,22 .http://doi.org/10.1089/gen.43.11.07Published, vol: 43 Issue 11: 202311月9日pdf下载

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Genetic Engineering & Biotechnology News 工程技术-生物工程与应用微生物

CiteScore

0.20

自引率

0.00%

发文量

210

审稿时长

3-6 weeks

期刊介绍： Genetic Engineering & Biotechnology News (GEN) is the flagship publication of Mary Ann Liebert, Inc. Launched in 1980, GEN was the first publication in this field and remains the key driver in the explosion of the industry, paving the way for the development of new technologies and applications, investment growth, and career opportunities. With nearly 40 years of publishing experience, GEN maintains unrivaled integrity, influence, and expertise that plays a pivotal role in driving the productivity and growth of the industry. Through its cornerstone Magazine, high-frequency newsletters, and dynamic suite of multimedia resources, GEN is the 360-degree resource that researchers and executives depend on for information that is pivotal for their organization’s success. GEN’s breadth of editorial coverage is unrivaled in the industry, providing exclusive coverage of the entire bioproduct lifecycle across five key pillars: Drug Discovery, Bioprocessing, OMICS, Translational Medicine, and Gene Editing.